Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.
暂无分享,去创建一个
R. Soiffer | R. Joyce | Shuli Li | J. Levine | D. Avigan | J. Rosenblatt | Haesook T. Kim | J. Antin | Salvia Jain | V. Ho | D. Tzachanis | E. Alyea | D. Stroopinsky | R. K. Leaf | J. Arnason | M. McMasters | A. Hamdan | Emma K. Logan | Mary Paty Bryant | A. Washington | L. Cole | A. Pyzer | M. Nahas | J. Bazemore | S. Stephenson | Amy Joyce | Jeremy G. Stewart | Myrna R Nahas | Abigail Washington | Malgorzata McMasters
[1] S. Paczesny,et al. B-cell activating factor (BAFF) plasma level at the time of chronic GvHD diagnosis is a potential predictor of non-relapse mortality , 2017, Bone Marrow Transplantation.
[2] J. Ritz,et al. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. , 2017, Blood.
[3] L. Turka,et al. Advances in targeting co‐inhibitory and co‐stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy , 2017, Immunological reviews.
[4] Stephanie J. Lee,et al. Late effects of blood and marrow transplantation , 2017, Haematologica.
[5] J. Ritz,et al. The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] J. Ritz,et al. Mechanistic approaches for the prevention and treatment of chronic GVHD. , 2017, Blood.
[7] S. Jaiswal,et al. T cell costimulation blockade for hyperacute steroid refractory graft versus-host disease in children undergoing haploidentical transplantation. , 2016, Transplant immunology.
[8] G. Freeman,et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. , 2016, The Journal of clinical investigation.
[9] W. Wood,et al. Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[10] Wei Wei,et al. Cellular and molecular mechanisms in graft‐versus‐host disease , 2016, Journal of leukocyte biology.
[11] G. Burmester,et al. Decreased use of glucocorticoids in biological-experienced patients with rheumatoid arthritis who initiated intravenous abatacept: results from the 2-year ACTION study , 2016, RMD Open.
[12] B. Storer,et al. Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease. , 2016, Blood.
[13] K. Minden,et al. Long‐Term Safety, Efficacy, and Quality of Life in Patients With Juvenile Idiopathic Arthritis Treated With Intravenous Abatacept for Up to Seven Years , 2015, Arthritis & rheumatology.
[14] C. Lengerke,et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey , 2015, Leukemia.
[15] Boquan Jin,et al. Type 1 regulatory T cells: a new mechanism of peripheral immune tolerance , 2015, Cellular and Molecular Immunology.
[16] J. Pidala,et al. Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results. , 2015, Biology of Blood and Marrow Transplantation.
[17] A. ElGhammaz. Current issues in chronic graft versus host disease , 2015 .
[18] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[19] Paul J Martin,et al. How we treat chronic graft-versus-host disease. , 2015, Blood.
[20] J. Jagdeo,et al. Treatment of chronic graft-versus-host disease with bortezomib. , 2014, Blood.
[21] S. Choi,et al. Current and emerging strategies for the prevention of graft-versus-host disease , 2014, Nature Reviews Clinical Oncology.
[22] M. Tanimoto,et al. Programmed Death-1 Pathway in Host Tissues Ameliorates Th17/Th1-Mediated Experimental Chronic Graft-versus-Host Disease , 2014, The Journal of Immunology.
[23] R. Nakhleh,et al. Abatacept use in graft-versus-host disease after orthotopic liver transplantation: a case report. , 2014, Transplantation proceedings.
[24] J. Ritz,et al. Current issues in chronic graft-versus-host disease. , 2014, Blood.
[25] P. Chevallier,et al. Increased Th17/Treg ratio in chronic liver GVHD , 2014, Bone Marrow Transplantation.
[26] M. Arnaout,et al. Abatacept in B7-1-positive proteinuric kidney disease. , 2013, The New England journal of medicine.
[27] A. Mehta,et al. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[28] G. Freeman,et al. Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. , 2013, Blood.
[29] I. Todorov,et al. Thymic Damage, Impaired Negative Selection, and Development of Chronic Graft-versus-Host Disease Caused by Donor CD4+ and CD8+ T Cells , 2013, The Journal of Immunology.
[30] M. Hochberg,et al. Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program , 2013, The Journal of Rheumatology.
[31] R. Kuiper,et al. The Role of Programmed Cell Death Ligand-1 (PD-L1/CD274) in the Development of Graft versus Host Disease , 2013, PloS one.
[32] Xiao-jun Huang,et al. Donor Th17 cells and IL‐21 may contribute to the development of chronic graft‐versus‐host disease after allogeneic transplantation , 2013, European journal of immunology.
[33] J. Ritz,et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. , 2012, Blood.
[34] Kailin Xu,et al. Altered balance between Th1 and Th17 cells in circulation is an indicator for the severity of murine acute GVHD. , 2012, Immunology letters.
[35] S. Held,et al. Novel treatment concepts for graft-versus-host disease. , 2012, Blood.
[36] M. Tanimoto,et al. Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. , 2012, Blood.
[37] E John Wherry,et al. T cell exhaustion , 2011 .
[38] B. Kurland,et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. , 2011, Blood.
[39] P. Chu,et al. Alloimmune Response Results in Expansion of Autoreactive Donor CD4+ T Cells in Transplants That Can Mediate Chronic Graft-versus-Host Disease , 2011, The Journal of Immunology.
[40] E. Holler,et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[41] R. Storb,et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] J. Ritz,et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. , 2009, Blood.
[43] G. Freeman,et al. PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.
[44] J. Ritz,et al. High Levels of B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease , 2007, Clinical Cancer Research.
[45] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[46] K. Schilbach,et al. PD-1–PD-L1 Pathway Is Involved in Suppressing Alloreactivity of Heart Infiltrating T Cells During Murine GVHD Across Minor Histocompatibility Antigen Barriers , 2007, Transplantation.
[47] Edward A Copelan,et al. Hematopoietic stem-cell transplantation. , 2006, The New England journal of medicine.
[48] Daniel Wolff,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[49] M. Dougados,et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. , 2005, The New England journal of medicine.
[50] T. Honjo,et al. PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. , 2001, Trends in immunology.
[51] P. Linsley,et al. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. , 1996, Journal of immunology.
[52] J. Serody,et al. The IL-17 differentiation pathway and its role in transplant outcome. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.